OS Therapies Inc: SATTERFIELD THOMAS A JR amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Thomas A. Satterfield Jr. filed an amended Schedule 13G with the SEC (accession 0001104659-26-125053) updating his beneficial ownership stake in OS Therapies Inc. The filing, submitted under the SEC's passive-investor disclosure regime, revises his previously reported position in the clinical-stage immunotherapy company. Specific share counts and percentage figures were not disclosed in the filing headline. The amendment matters because 13G updates signal shifts in large holders' positions that can influence sentiment in thinly traded small-cap biotech names. Investors will watch for the full filing details to gauge whether Satterfield's stake crossed the 5% threshold or reflected passive portfolio rebalancing.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Satterfield Thomas A Jr, OS Therapies Inc